By Team Trilogy

Welcome to “The Strength of Our SHIELD”! In this four-part series, we’ll be exploring the technologies and partnerships behind our latest cleanliness initiative, the Trilogy SHIELD Program, and how it continues to pave the way towards senior living’s next chapter. To learn more about the Trilogy SHIELD Program, please click here.

When our world was first changed by COVID-19, providers everywhere began to seek out solutions that could meet a once-in-a-century moment. When it came to caring for the population’s most vulnerable members, we knew that no stone could be left unturned, and that all treatments options deserved to be explored, investigated, and if found effective and safe, implemented into our response. That’s why, in partnership with PCA Pharmacy, we are now proud to offer Bamlanivimab – a monoclonal antibody therapy for those with mild to moderate cases of COVID-19. 

Credit: Eli Lily 

Proven in clinical trials to reduce hospitalization for those at high-risk of disease, bamlanivimab creates antibodies capable of fighting off viruses such as SARS-CoV-2. Now available to all qualifying Trilogy residents, this treatment promises to reduce the risk of infection for those not already afflicted by COVID-19. Here’s what our Chief Nursing Officer, Barbara DiMercurio-Revelette, had to say about the effectiveness of bamlanivimab: 

“At Trilogy, the health and well-being of our residents drives everything we do, so when we hear about a new treatment that has the potential to improve their lives, we make every effort to pursue it. We couldn’t be more grateful for PCA Pharmacy, whose resources and expertise have been invaluable when developing and executing our response to the pandemic. I am hopeful that this therapy will be a difference-maker for our residents who are qualified to receive it.”

Click here to read the FDA’s detailed summary on bamlanivimab and its emergency use authorization!